Aion Therapeutic Inc. (ANTCF) Stock Price & Analysis
Aion Therapeutic Inc. (ANTCF) — price $0.002 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.26M.
Educational signal · not a buy or sell recommendation · How to read this
Aion Therapeutic Inc. · ANTCF
Aion Therapeutic Inc. focuses on developing medical cannabis products within Canada. The company rebranded from Osoyoos Cannabis Inc.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.002 | |
| Change on the day | 0.00% | |
| Market capitalisation | $1.26M | — |
| Price / earnings (trailing) | -1.99 | |
| Shares traded on the day | 15.0K |
Price & events
Other perspectives
Council score for Aion Therapeutic (ANTCF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 2, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Aion Therapeutic (ANTCF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Aion Therapeutic Inc. (ANTCF) is the company analyzed here. In Q3 FY2025 it reported revenue of C$544,985 and net income of -C$292,464. The market values it at $1.26M.
What do the latest results show for Aion Therapeutic (ANTCF)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of C$544,985.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | C$544,985 | -C$292,464 | -C$0.0006 (diluted) |
| Q2 FY2025 | C$347,625 | -C$582,813 | -C$0.0012 (diluted) |
| Q1 FY2025 | C$434,860 | -C$370,811 | -C$0.0010 (diluted) |
| Q4 FY2024 | C$145,436 | -C$5M | -C$0.01 (diluted) |
What are the financial strengths and risks for Aion Therapeutic (ANTCF)?
Short answer · as of
The distress and quality screens read Piotroski F 3. Trailing ratios: ROE 190.6% · current ratio 0.12 · free-cash-flow yield -34.0%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ANTCF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ANTCF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About ANTCF
These answers are editorial: 1 of these 1 answer is drawn from the ANTCF research dossier (written Jun 1, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What do analysts say about ANTCF stock?
There is no available analyst coverage for ANTCF stock due to its OTC listing and small market capitalization. Therefore, no analyst consensus, valuation metrics, or growth considerations are available.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 11 figures on this page — 8 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com